SEGMENT INFORMATION (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2025 USD ($) segment	Mar. 31, 2024 USD ($)
Segment Reporting [Abstract]
Number of operating segments | segment	1
Number of reportable segments | segment	1
Segment Reporting Information [Line Items]
Total revenues	$ 202	$ 98
Operating expenses
Research and development	6,124	3,708
General and administrative	3,275	3,770
Operating loss	(9,197)	(7,380)
Income tax expense	0	0
Loss from continuing operations	(8,603)	(6,241)
Net loss	(8,611)	(6,249)
Reportable Segment
Operating expenses
Other segment items	1,026	805
General and administrative	3,275	3,770
Total operating expenses	9,399	7,478
Operating loss	(9,197)	(7,380)
Other income, net	594	1,139
Loss from continuing operations before income taxes	(8,603)	(6,241)
Income tax expense	0	0
Loss from continuing operations	(8,603)	(6,241)
Loss from discontinued operations, net of income taxes	(8)	(8)
Net loss	(8,611)	(6,249)
Royalty revenues | Reportable Segment
Segment Reporting Information [Line Items]
Total revenues	202	98
Repibresib (VYN201) | Reportable Segment
Operating expenses
Research and development	2,577	1,897
VYN202 | Reportable Segment
Operating expenses
Research and development	$ 2,521	$ 1,006